-
- Grabow D.
- Kaiser M.
- Hjorth L.
- Byrne J.
- Alessi D.
- Allodji R.S.
- et al.
The PanCareSurFup cohort of 83,333 five-year survivors of childhood cancer: a cohort from 12 European countries.
Eur J Epidemiol. 2018; 33: 335-349
-
- Melero I.
- Berman D.M.
- Aznar M.A.
- Korman A.J.
- Gracia P.érez
- Haanen J J.L.
Evolving synergistic combinations of targeted immunotherapies to combat cancer.
Nat Rev Cancer. 2015; 15: 457-472
-
- Geoerger B.
- Kang H.J.
- Yalon-Oren M.
- Marshall L.V.
- Vezina C.
- Pappo A.
- et al.
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
. 2020; 21: 121-133
-
- Geoerger B.
- Bergeron C.
- Gore L.
- Sender L.
- Dunkel I.J.
- Herzog C.
- et al.
Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma.
Eur J Cancer. 2017; 86: 358-363
-
- Dunkel I.J.
- Doz F.
- Foreman N.K.
- Hargrave D.
- Lassaletta A.
- et al.
Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies: Safety, efficacy, biomarker, and pharmacokinetics-CheckMate 908.
Neuro Oncol. 2023; 25: 1530-1545
-
- Geoerger B.
- Zwaan C.M.
- Marshall L.V.
- Michon J.
- Bourdeaut F.
- Casanova M.
- et al.
Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1-2 study.
Lancet Oncol. 2020; 21: 134-144
-
- Davis K.L.
- Fox E.
- Merchant M.S.
- Reid J.M.
- Kudgus R.A.
- Liu X.
- et al.
Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial.
Lancet Oncol. 2020; 21: 541-550
-
- Bouffet E.
- Larouche V.
- Campbell B.B.
Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency.
J Clin Oncol. 2016; 34 ()
-
- Davis K.L.
- Fox E.
- Isikwei E.
- Reid J.M.
- Liu X.
- Minard C.G.
- et al.
A phase I/II trial of nivolumab plus ipilimumab in children and young adults with relapsed/refractory solid tumors: a Children's Oncology Group Study ADVL1412.
Clin Cancer Res. 2022; 28: 5088-5097
-
- Ciccolini J.
- Barbolosi D.
- André N.
- Benzekry S.
- Barlesi F.
Combinatorial immunotherapy strategies: most gods throw dice, but fate plays chess.
Ann Oncol. 2019; 30: 1690-1691
-
- Pasquier E.
- Kavallaris M.
- André N.
Metronomic chemotherapy: new rationale for new directions..
Nat Rev Clin Oncol. 2010; 7: 455-465
-
- André N.
- Tsai K.
- Carré M.
- Pasquier E.
Metronomic chemotherapy: direct targeting of cancer cells after all?.
Trends Cancer. 2017; 3: 319-325
-
The anti-angiogenic basis of metronomic chemotherapy.
Nat Rev Cancer. 2004; 4: 423-436
-
Metronomics: towards personalized chemotherapy.
Nat Rev Clin Oncol. 2014; 11: 413-431
-
Taking regulatory T cells into medicine.
J Exp Med. 2021 7; 218e20210831
-
- Ghiringhelli F.
- Menard C.
- Puig P.E.
- Ladoire S.
- Roux S.
- Martin F.
- et al.
Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients.
Cancer Immunol Immunother. 2007; 56: 641-648
-
Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer.
Int J Cancer. 2013; 133: 98-107
-
Tumor microenvironmental conversion of natural killer cells into myeloid-derived suppressor cells.
Cancer Res. 2013; 73: 5669-5681
-
Early-phase treatment by low-dose 5-fluorouracil or primary tumor resection inhibits MDSC-mediated lung metastasis formation.
Anticancer Res. 2015; 35: 4425-4431
-
5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity.
Cancer Res. 2010; 70: 3052-3061
-
Antitumor effects of anti-CD40/CpG immunotherapy combined with gemcitabine or 5-fluorouracil chemotherapy in the B16 melanoma model.
Int Immunopharmacol. 2013; 17: 1141-1147
-
- Peereboom D.
- Alban T.
- Grabowski M.
- et al.
Metronomic capecitabine as an immune modulator in glioblastoma patients reduces myeloid-derived suppressor cells.
JCI Insight. 2019; 4e130748
-
Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents.
Cancer Cell. 2015; 28: 690-714
-
Chemotherapeutic agents in low noncytotoxic concentrations increase immunogenicity of human colon cancer cells.
Cell Oncol. 2011; 34: 97-106
-
Dual therapeutic efficacy of vinblastine as a unique chemotherapeutic agent capable of inducing dendritic cell maturation.
Cancer Res. 2009; 69: 6987-6994
-
Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism.
J Immunol. 2009; 183: 137-144
-
- Berlanga P.
- Pierron G.
- Lacroix L.
- Chicard M.
- Adam de Beaumais T.
- Marchais A.
The European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies.
Cancer Discov. 2022 2; 12: 1266-1281
-
- Kilburn L.B.
- Kocak M.
- Baxter P.
- Poussaint T.Y.
- Paulino A.C.
- et al.
A pediatric brain tumor consortium phase II trial of capecitabine rapidly disintegrating tablets with concomitant radiation therapy in children with newly diagnosed diffuse intrinsic pontine gliomas.
Pedia Blood Cancer. 2018; 65https://doi.org/10.1002/pbc.26832
-
- Ceschi A.
- Noseda R.
- Palin K.
- Verhamme K.
Immune checkpoint inhibitor-related cytokine release syndrome: analysis of WHO global pharmacovigilance database.
Front Pharm. 2020; 11557
-
- Maharjan R.
- Choi J.U.
- Kweon S.
- Pangeni R.
- Lee N.K.
- Park S.J.
- et al.
A novel oral metronomic chemotherapy provokes tumor specific immunity resulting in colon cancer eradication in combination with anti-PD-1 therapy..
Biomaterials. 2022; 281121334
-
- Skavatsou E.
- Semitekolou M.
- Morianos I.
- Karampelas T.
- Lougiakis N.
- Xanthou G.
- Tamvakopoulos C.
Immunotherapy combined with metronomic dosing: an effective approach for the treatment of NSCLC.
Cancers. 2021; 13: 1901
-
- Vicier C.
- Isambert N.
- Cropet C.
- Hamimed M.
- Osanno L.
- Legrand F.
- et al.
MOVIE: a phase I, open-label, multicenter study to evaluate the safety and tolerability of metronomic vinorelbine combined with durvalumab plus tremelimumab in patients with advanced solid tumors.
ESMO Open. 2022; 7100646
-
- Berland M.
- Padovani L.
- Rome A.
- Pech-Gourg G.
- Figarella-Branger D.
- André N.
Sustained Complete Response to Metronomic Chemotherapy in a Child with Refractory Atypical Teratoid Rhabdoid Tumor: A Case Report..
Front Pharm. 2017; 8792
-
- Winnicki C.
- Leblond P.
- Bourdeaut F.
- Pagnier A.
- Paluenzela G.
- Chastagner P.
- et al.
Retrospective National "Real Life" Experience of the SFCE with the Metronomic MEMMAT and MEMMAT-like Protocol.
J Clin Med. 2023; 12: 1415
-
- Peyrl A.
- Chocholous M.
- Sabel M.
- Lassaletta A.
- Sterba J.
- et al.
I. Sustained Survival Benefit in Recurrent Medulloblastoma by a Metronomic Antiangiogenic Regimen: A Nonrandomized Controlled Trial.
JAMA Oncol. 2023; ()
-
- Pasqualini C.
- Rubino J.
- Brard C.
- et al.
Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSé-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium.
Eur J Cancer. 2021; 150: 53-62
-
- Loeb D.M.
- Lee J.W.
- Morgenstern D.A.
- Samson Y.
- Uyttebroeck A.
- Lyu C.J.
- Van Damme A.
- Nysom K.
- Macy M.E.
- Zorzi A.P.
- Xiong J.
- Pollert P.
- Joerg I.
- Vugmeyster Y.
- Ruisi M.
- Kang H.J.
Avelumab in paediatric patients with refractory or relapsed solid tumours: dose-escalation results from an open-label, single-arm, phase 1/2 trial..
Cancer Immunol Immunother. 2022; 71: 2485-2495
-
- Verschuur A.
- Heng-Maillard M.A.
- Dory-Lautrec P.
- Truillet R.
- Jouve E.
- Chastagner P.
- Leblond P.
- Aerts I.
- Honoré S.
- Entz-Werle N.
- Sirvent N.
- Gentet J.C.
- Corradini N.
- André N.
Metronomic Four-Drug Regimen Has Anti-tumor Activity in Pediatric Low-Grade Glioma; The Results of a Phase II Clinical Trial.
Front Pharm. 2018; 900950
Plaats een reactie ...
Reageer op "Solide tumoren: Metronomische chemotherapie = dagelijks lage doses chemo naast immuuntherapie met nivolumab verbetert effectiviteit bij vormen van kanker met solide tumoren bij kinderen"